Bioniche Life Sciences Inc. Announces the Appointment of a New Chief Executive Officer

BELLEVILLE, ON, Nov. 4, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has hired Dr. Michael Berendt as its new CEO effective immediately. Dr. Berendt replaces Mr. Graeme McRae in this role. Earlier this year, Mr. McRae announced his intention to retire and assume the role of Founder and Chairman Emeritus of the Company's Board of Directors.

"The Board of Directors, management team, employees and shareholders acknowledge Graeme's significant contribution, while welcoming Dr. Berendt to the Bioniche team," said Mr. James Rae, Chairman of the Bioniche Life Sciences Inc. Board of Directors. "Dr. Berendt has an established background in the life sciences sector, most recently serving as President & CEO of Aegera Therapeutics Inc. in Montréal, Québec."

Dr. Berendt held positions of increasing responsibility in the U.S. research departments of Pfizer, Inc. and Bayer Corporation before becoming Managing Director, Life Sciences Sector of AEA Investors, then Managing Director of Research Corporation Technologies. In 2006, he became the President & CEO of Aegera, which was sold to Pharmascience in 2011.

Dr. Berendt graduated with a B.S. from Ohio Dominican University, a M.S. from Miami University, and a Ph.D. in Medical Microbiology and Immunology from Drexel University. Dr. Berendt is a Director on the Boards of Waters Corporation and NeoMed Institute. He serves as Executive Chairman of Anchor Therapeutics and serves as Chairman of Alethia Biothérapeutiques.

Dr. Berendt will be attending the Company's Annual and Special Meeting of Shareholders, being held on Tuesday, November 5, 2013 at 4:00 p.m. Eastern in Belleville, Ontario.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and One Health. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


SOURCE Bioniche Life Sciences Inc.



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.